Entity
  • PEP-Therapy

    Created in 2014
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    2,083
  • Activities

  • Technologies

  • Entity types

  • Location

    111 Av. de France, 75013 Paris, France

    Paris

    France

  • Employees

    Scale: 2-10

    Estimated: 14

  • SIREN

    799395215
  • Engaged corporates

    4
    3 1
  • Added in Motherbase

    5 years, 6 months ago
Description
  • Value proposition

    Innovative peptides as targeted therapies for oncology

    PEP-Therapy is a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology.

    PEP-010, first drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile.
    PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors.

    PEP-Therapy was founded in 2014 and builds on research results from Institut Curie and Sorbonne University. The company is backed by international investors.

    cell penetrating peptide, protein-protein interaction, targeted therapies, oncology, clinical trial, and cancer

  • Original language

    Innovative peptides as targeted therapies for oncology

    PEP-Therapy is a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology.

    PEP-010, first drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile.
    PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors.

    PEP-Therapy was founded in 2014 and builds on research results from Institut Curie and Sorbonne University. The company is backed by international investors.

  • PEP-Therapy, Innovative peptides as targeted therapies for oncology

    PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology.

  • https://pep-therapy.com/
Corporate interactions BETA
Corporate TypeTweets Articles
LUTECH LUTECH
Other

15 Mar 2024


Medicen Paris Region
Medicen Paris Region
Public business cluster, French Cluster, Civic and Social Organizations
Medicen Paris Region
Public business cluster, French Cluster, Civic and Social Organizations
Other

8 Mar 2024


Paris Biotech Santé
Paris Biotech Santé
Startup accelerator & VC, Civic and Social Organizations
Paris Biotech Santé
Startup accelerator & VC, Civic and Social Organizations
Other

20 Jul 2023


Institut Curie
Institut Curie
Health, Hospitals and Health Care
Institut Curie
Health, Hospitals and Health Care
Other

30 Sep 2021


Similar entities
Loading...
Loading...
Social network dynamics